Joint Formulary Newsletter
Bedfordshire and Luton Joint Formulary Newsletter
January 2020, Number 2
Incorporates Key Recommendations from The Bedfordshire and Luton Joint Prescribing Committee (JPC) 4th December 2019
The Bedfordshire and Luton Joint Formulary (a combined medicines formulary for use by BCCG, LCCG, Bedford Hospital and the Luton and Dunstable University Hospital) is now ‘live’. It can be accessed here
Unless otherwise stated decisions made apply to all organisations in the Joint Formulary Group.
|FORMULARY TRAFFIC LIGHT STATUS INFORMATION|
|RED||RED - Hospital Only - to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment|
|AMBER||Amber medicines are considered suitable for GP prescribing following specialist initiation|
|GREEN||These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations|
|SCG||Shared Care - These medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place, status reverts to RED.|
|BLACK||A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. DO NOT PRESCRIBE|
|The following ADDITIONS to the Joint Formulary were agreed at the JPC Committee Meeting|
Environmental considerations and inhaler choice (joint formulary chapter 3: respiratory)
Following the publication of the NICE Asthma patient decision aid, a paper was prepared for consideration which outlined cost-effective, low carbon inhaler choices.
As a result, the JPC approved the following additions to the Primary Care Respiratory Guidelines:-
It was agreed that there would be a low carbon inhaler formulary option available for each stage in the treatment pathway, should patients request it.
Primary Care Management of Adult Female Urinary Incontinence (joint formulary chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders)
Following an update to NICE guidelines, the following urinary incontinence treatments were added to formulary:
Bedfordshire and Luton Prescribing Guideline for Dry Eye Management in Adults (joint formulary chapter 11: Eye)
The aim of the guideline is to provide information to Primary Care Prescribers around the treatment steps for dry eye and review the most cost effective brands (branded prescribing recommended in Primary Care).
CCGs will use Scriptswitch/Optimise to support primary care on which brand to prescribe. To facilitate this, secondary care teams will recommend generic products. The following eye drops were added onto the formulary:
N.B: self care is recommended for mild to moderate dry eyes in line with national guidance (Conditions for which over the counter items should not routinely be prescribed in primary care).
Aviptadil/phentolamine intracavernosal injection (Invicorp®) for erectile dysfunction (joint formulary chapter 7: Obstetrics, Gynaecology, and urinary-tract disorders)
Rasagiline for Parkinson’s Disease (joint formulary chapter 4: Central Nervous System)
Slenyto® brand of melatonin for ADHD
Slenyto® remains a ‘red drug’ – for specialist initation and continuation as per licensed indication pending a business case to accurately determine patient numbers.
|Hospital Drug and Therapeutic Committee Updates|
The following additions to the Joint Formulary were ratified at Bedford Hospital DTC:-
The following additions to the Joint Formulary were ratified at the Luton & Dunstable Hospital DTC:-
|CCG Prescribing Committees|
BCCG Prescribing Committee
LCCG prescribing committee
Palmdoc blood glucose test strips
|Wound Care Formulary Group (Ratified by the JPC)|
UrgoTul SSD has been discontinued in the UK due to new licensing. The replacement product is UrgoTul Silver.
|Decisions Made By Joint Formulary Group (Ratified by the JPC)|
Cannabis based products
Post JPC the following NICE technology appraisals were published:
Joint Formulary updates following publication of NICE Technology Appraisal Guidance CCG Commissioned
Dapagliflozin with insulin for treating type 1 diabetes, Technology appraisal guidance [TA597] – Joint Formulary updated to reflect TA, for specialist initiation and GP continuation.
NHSE Commissioned- New drugs added
(Recommended via Cancer Drugs Fund) – TA link added to formulary website
(Recommended via Cancer Drugs Fund) – added to the Formulary
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab,Technology appraisal guidance [TA612], – added to the Formulary